Developing a targeted treatment for multiple myeloma.

Oncopeptides has been granted a priority review by the U.S. Food and Drug Administration, for the New Drug Application of melflufen in combination with dexamethasone for the treatment of adult patients with multiple myeloma. Oncopeptides is a fully integrated global biotech company committed to bringing innovation to patients with an unmet medical need and improving patient lives.